{'fraction_non_alphanumeric': 0.01667735728030789, 'fraction_numerical': 0.0, 'mean_word_length': 5.190476190476191, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Using Merged Cancer Registry Data for Survival Analysis in Patients Treated with Integrative Oncology: Conceptual Framework and First Results of a Feasibility Study

Survival analysis is the basis for research into all types of treatments aimed at prolonging the overall survival of a cancer entity. Before we use data from a cancer registry at the Clinic Arlesheim (CRCA) for more sophisticated survival analysis in relation to integrative oncology treatments, we wanted to learn more about the possible differences between the clientele in this database and the public. In a first step we compared survival rates for breast cancer and pancreatic cancer analyzed from CRCA-data with the cor-responding survival rate (all stages) available at the Robert-Koch-Institute. Furthermore, we differentiated the survival rates from CRCA-patients with respect to the fraction of the survival time in the care of the clinic Arlesheim. While the survival rates of CRCA-patients with breast cancer or with pancreatic cancer show similar survival rates compared to corresponding data from the Robert-Koch-Institute, the sensitivity analysis suggests that the longer the fraction of the survival time in the care of the clinic Arlesheim the higher the expected survival rates. In conclusion, the analysis and comparison of the survival rates of a clinical population of a cancer registry, such as CRCA, may lead to a better identification of responders and non-responders and thus in the long run may help to optimise integrative and patient cantered treatment strategies.